MWNA
PCVX icon

Marshall Wace North America’s Vaxcyte PCVX Stock Holding History

Marshall Wace North America’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-38,856
Closed -$1.23M – 1412
2020
Q2 		$1.23M Buy
+38,856
New +$1.25M 0.01% 708

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace North America's PCVX Position: Q3 2020 in Review

Marshall Wace North America sold out of Vaxcyte (PCVX) in Q3 2020, closing a stake of 38,856 shares — an estimated $1.23M sold.

Marshall Wace North America first reported a position in PCVX in Q2 2020 and held it in 1 quarter. The position peaked at $1.23M in Q2 2020. 60 funds tracked by Wall St. Rank hold PCVX as of Q3 2020.

  • Marshall Wace North America reported no remaining Vaxcyte position as of Q3 2020 after selling out during the quarter.
  • Marshall Wace North America sold 38,856 Vaxcyte shares in Q3 2020, an estimated $1.23M.
  • Marshall Wace North America first reported a position in Vaxcyte in Q2 2020 and held it in 1 quarter.
  • Marshall Wace North America's Vaxcyte position peaked at $1.23M in Q2 2020.
  • 60 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2020.

Based on Marshall Wace North America's 13F filing for Q3 2020, filed 16 Nov 2020.